Authors
Michelle Rosenzwajg, Roberta Lorenzon, Patrice Cacoub, Hang Phuong Pham, Fabien Pitoiset, Karim El Soufi, Claire RIbet, Claude Bernard, Selim Aractingi, Beatrice Banneville, Laurent Beaugerie, Francis Berenbaum, Julien Champey, Olivier Chazouilleres, Christophe Corpechot, Bruno Fautrel, Arsène Mekinian, Elodie Regnier, David Saadoun, Joe-Elie Salem, Jérémie Sellam, Philippe Seksik, Anne Daguenel-Nguyen, Valérie Doppler, Jéremie Mariau, Eric Vicaut, David Klatzmann
Publication date
2019/2/1
Journal
Annals of the rheumatic diseases
Volume
78
Issue
2
Pages
209-217
Publisher
BMJ Publishing Group Ltd
Description
Objective
Regulatory T cells (Tregs) prevent autoimmunity and control inflammation. Consequently, any autoimmune or inflammatory disease reveals a Treg insufficiency. As low-dose interleukin-2 (ld-IL2) expands and activates Tregs, it has a broad therapeutic potential.
Aim
We aimed to assess this potential and select diseases for further clinical development by cross-investigating the effects of ld-IL2 in a single clinical trial treating patients with 1 of 11 autoimmune diseases.
Methods
We performed a prospective, open-label, phase I–IIa study in 46 patients with a mild to moderate form of either rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Behcet’s disease, granulomatosis with polyangiitis, Takayasu’s disease, Crohn’s disease, ulcerative colitis, autoimmune hepatitis and sclerosing cholangitis. They all received ld-IL2 (1 million IU/day) for 5 days, followed by fortnightly injections …
Scholar articles
M Rosenzwajg, R Lorenzon, P Cacoub, HP Pham… - Annals of the rheumatic diseases, 2019